Pharsight

Drugs that contain Umeclidinium Bromide

1. Incruse Ellipta patents expiration

INCRUSE ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 2 months from now)

US7488827 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(1 year, 2 months from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 5 months from now)

US9333310 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXO GRP ENGLAND Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8161968 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2028

(3 years from now)

US8201556 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2029

(4 years from now)

US8534281 GLAXO GRP ENGLAND Manifold for use in medicament dispenser
Mar, 2030

(6 years from now)

US8746242 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jun 9, 2022

Market Authorisation Date: 30 April, 2014

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

INCRUSE ELLIPTA family patents

Family Patents